Life Science Investing Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance
Life Science Investing Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal
Life Science Investing Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials
Life Science Investing Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds
Life Science Investing Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds
Life Science Investing Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery
Life Science Investing Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission
Life Science Investing Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference
Life Science Investing Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications
